The hematopoietic growth factors interleukin-3 (IL-31, IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF) regulate the survival, maturation, and activation of eosinophils. Corticosteroids in contrast have a negative effect both on the hematopoietic process and the function of eosinophils. We have unexpectedly observed synergy between IL-5 and glucocorticoids such as dexamethasone and hydrocortisone for induction of the MHC class II antigens HLA-DR and HLA-DP on eosinophils isolated from human blood. Similarly glucocorticoids enhanced GM-CSF and IL-3, but not interferon y (IFNy), induced expression of these antigens. Expression of a third MHC class II molecule, HLA-OSINOPHILS PLAY a central role in the pathology of allergic diseases such as asthma, where their release of granule proteins and lipid mediators is thought to be responsible for the tissue damage observed.',* Although normal blood eosinophils do not express major histocompatability complex (MHC) class 11 antigens or the adhesion molecule intercellular adhesion molecule 1 (ICAM-l), their expression can be induced in vitro after stimulation with cytokines. These eosinophils are subsequently able to present antigen to and activate T lymphocyte^.^-^ Cytokines shown to mediate eosinophil activation in culture include IL-3, IL-5, GM-CSF, and IFNy. Eosinophils in sputum samples from asthmatic individuals have been shown to express both HLA-DR and ICAM-1, reflecting the immune activation occurring during the disease process in Glucocorticoids are used as anti-inflammatory agents in the treatment of allergy where they prevent accumulation of eosinophils at the site of disease and reduce the numbers of circulating eosinophil^.^^^ In vitro experiments show inhibition of cytokine-mediated eosinophil survival by glucocorticoids'O''z and of cytokine-induced upregulation of complement receptor type 3."
OSINOPHILS PLAY a central role in the pathology of allergic diseases such as asthma, where their release of granule proteins and lipid mediators is thought to be responsible for the tissue damage observed.',* Although normal blood eosinophils do not express major histocompatability complex (MHC) class 11 antigens or the adhesion molecule intercellular adhesion molecule 1 (ICAM-l), their expression can be induced in vitro after stimulation with cytokines. These eosinophils are subsequently able to present antigen to and activate T lymphocyte^.^-^ Cytokines shown to mediate eosinophil activation in culture include IL-3, IL-5, GM-CSF, and IFNy. Eosinophils in sputum samples from asthmatic individuals have been shown to express both HLA-DR and ICAM-1, reflecting the immune activation occurring during the disease process in Glucocorticoids are used as anti-inflammatory agents in the treatment of allergy where they prevent accumulation of eosinophils at the site of disease and reduce the numbers of circulating eosinophil^.^^^ In vitro experiments show inhibition of cytokine-mediated eosinophil survival by glucocorticoids'O''z and of cytokine-induced upregulation of complement receptor type 3."
We have recently described how dexamethasone acts in synergy with GM-CSF or IL-3 to upregulate HLA-DR, DP, and DQ antigen expression by purified human blood monocytes.''.'' These cells respond weakly to either GM-CSF or IL-3 for upregulation of MHC class I1 antigen expression in comparison to the levels expressed after stimulation with IFNy or IL-4. Because eosinophils are one of the few cell types reported to respond to these cytokines for increased MHC class I1 antigen expression, the present study was designed to assess whether glucocorticoid hormones similarly enhance MHC expression by blood eosinophils. We present studies on the effects of dexamethasone and hydrocortisone, as well as three nonglucocorticoid steroid hormones, on cytokine induction of MHC class I1 antigen expression, and other antigen presenting functions of highly purified human blood eosinophils.
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were then washed and incubated on ice for 30 minutes with anti-CD16 antibody. The cells were washed and incubated for a further 20 minutes with rat-antimouse IgG2a-coated immunomagnetic partcles. The magnetically labeled neutrophils were depleted by passing the granulocytes through a magnetic cell separation column (Miltenyi Biotec, Berisch-Gladbach, Germany, and Becton-Dickinson). This procedure resulted in greater than 99.5% pure eosinophils (CD9+ granulocytes) with no detectable lymphocyte or monocyte contamination, as determined by flow cytometry.
Eosinophil culture. Purified eosinophils were cultured at a density of 1 X 106/mL in 96-well flat-bottomed plates (Nunc, Life Technologies, Paisley, Scotland) in a total volume of 200 pL RPMI 1640 medium supplemented with 10% FCS, 2 m m o E L-glutamine, 100 UlmL penicillin and 100 pg/mL streptomycin (all purchased from GIBCO, Life Technologies, Paisley, Scotland) at 37°C in 5% CO2. Cytokines and steroids were added at concentrations indicated in the results section. MHC class I1 expression on cultured eosinophils was usually assessed at day 5 or 6 of culture.
Flow cytometry. All flow cytometry was performed using an EPICS Profile I1 cell analyser (Coulter Electronics Limited, Luton, UK). Approximately 1 X 105 cells were incubated in round-bottomed 96-well plates in the presence of the appropriate antibody and 10 pg/mL goat IgG as a blocking agent for 1 hour at 4°C. The cells were then washed twice with phosphate-buffered saline containing 1% bovine serum albumin (Sigma). For unconjugated antibodies goat-antimouse IgG-FITC was added to the cells for a further 30-minute incubation. Live cells were gated according to forward-and side-light-scatter profile that had previously been determined for live cells by propidium iodide (Sigma) staining. Data was collected from 3,000 to 5,000 cells/sample. Gates for positively or negatively staining cell analysis were adjusted so 4 % to 5% of the cells stained positive after treatment with a control mouse IgG antibody (see Fig  1, C and D) . The same gate was used on cells treated with specific antibody to determine the percentage of positively staining cells. The log mean fluorescence intensity values were assessed for the whole cell population, an increase in the value indicating an increase in the cell surface antigen density at the population level.
lnftuenza virus hemagglutinin peptide-reactive T-cell clone. Cloning and maintenance of an influenza virus hemagglutinin peptide-reactive T-cell clone, HA1.7, has been previously described in detail." This clone is specific for residues 307-319 HLA-DR expressing eosinophils und antigen presentution t o HA1.7 T-cell clone. Highly purified eosinophils were cultured for 24 hours as described above in the presence of 50 U/mL GM-CSF with and without the presence of IO-* m o a dexamethasone. The eosinophils were then washed three times in medium and viable cells counted using trypan blue (Sigma). Eosinophils were resuspended at the appropriate cell concentration in RPMI 1640 medium supplemented with 5% screened, heat-inactivated human A' serum (National Blood Transfusion Service, Edgware), 2 mmolL L-glutamine, 100 U/mL penicillin, and 100 pg/mL streptomycin (GIBCO). T-cell proliferation assays were set up using round-bottomed 96-well plates with doubling dilutions of eosinophils ranging from 2.5 X 10' to 2 X IO4 eosinophils/well. Cloned T lymphocytes were added at 2 X IO4 cells/well in the presence or absence of 1 pg/mL HA peptide 307-319. The cells were cultured for 48 hours at 37°C in 5% CO2 before pulsing with tritiated thymidine ( I pCi/well, Amersham International Plc, Amersham, UK) for the last 6 hours of culture. Proliferation was determined by 'H-thymidine incorporation measured using a liquid-scintillation beta counter (Pharmacia).
RESULTS
Contrasting effects of dexamethasone on IFNy-and GM-CSF-induced expression of HLA class I1 antigens by human eosinophils. Eosinophils were purified from peripheral blood by density-gradient centrifugation and use of a magnetic cell separator to deplete CD16' neutrophils. The cells were greater than 99.5% pure based on forward-and sidescatter analysis by flow cytometry (data not shown) and by staining with an antibody specific for CD9 that is expressed by eosinophils but not neutrophils (Fig 1A) . These cells did not express MHC class I1 antigens (Fig 1B; less than 4% HLA-DR' in all experiments). To determine the effect of glucocorticoids on GM-CSF-induced expression of the three major MHC class I1 antigens, HLA-DR, -DP, and -DQ, eosinophils were cultured for 5 days with 50 U/mL recombinant human GM-CSF, a concentration of cytokine found to log mean fluorescence intensity give optimal cell survival in culture, in the presence or absence of dexamethasone. Stimulation with GM-CSF induced 28% of the eosinophils to express HLA-DR (Fig lC) , whereas addition of lo-* m o m dexamethasone enhanced expression to 50% positive cells (Fig 1D) . In this experiment, no expression of HLA-DP or HLA-DQ was found with any of the treatments. In a second donor, GM-CSF induced both HLA-DR and HLA-DP expression (Fig 2A) which were enhanced by dexamethasone. Cells cultured for 5 days in medium or dexamethasone alone did not survive. The concentrations of glucocorticoids used in all experiments were found to have no effect on cell viability in the presence of cytokine.
Variability for the induction of MHC class I1 expression was noted amongst eosinophils isolated from different donors. GM-CSF induced HLA-DR expression in all donors tested, with levels varying from 21% to 94%. In 10 of 13 experiments, dexamethasone enhanced expression of HLA-DR, and in the three experiments where no enhancement was observed, expression induced by GM-CSF alone was very high, making it difficult to see over this baseline. GM-CSF-induced HLA-DP expression in six of seven individuals tested (range, 8% to 34%; day 0, less than 2% in all cases) with marked upregulation of HLA-DP antigen by dexamethasone being observed ( Fig. 2A) . One individual failed to show HLA-DP expression after any of these treatments when tested in five experiments over a 3-month period. GM-CSF, with or without dexamethasone, failed to induce HLA-DQ expression in all donors tested (Fig 2A) .
IFNy has previously been reported to induce MHC class I1 expression on eosinophils and to enhance GM-CSF upregulation of these antigens4 Although dexamethasone enhanced the expression of HLA-DR induced by GM-CSF (42% to 70%), induction by IFNy was inhibited (59% to 37%). Cells cultured in the presence of both cytokines showed greater expression of HLA-DR than with either cytokine alone (94% positive cells); however, dexamethasone had little effect on this expression (90%).
Effect of dexamethasone on IL-3-induced expression of HLA class II antigens. The effect of dexamethasone on IL-3 induction of MHC class I1 antigens was also tested because this cytokine shares many biologic properties with GM-CSF, including the capacity to stimulate HLA-DR expression by eosinophils: IL-3, used between 3 and 250 ng/mL, induced very high expression of HLA-DR in all three individuals tested. The further addition of dexamethasone did not significantly enhance the percentage of positively staining cells, but did induce a clear increase in the log mean fluorescence intensity. In a representative experiment, IL-3 alone induced a log mean fluorescence intensity of 41, which was increased to 92 in the presence of lo-* m o m dexamethasone.
Enhancement of HLA-DP expression by dexamethasone was also observed with all three donors tested. In a representative experiment for HLA-DP expression (Fig 3) IL-3 alone induced 59% of cells to express HLA-DP. Dexamethasone at m o m increased expression to 82% and at lo-* mol/ L to 92%. Although one individual was induced to express significant levels (50%) after stimulation with IL-3 plus dexamethasone (Fig 3) , expression of HLA-DQ was not upregu- For personal use only. on November 11, 2017. by guest www.bloodjournal.org From lated after exposure to IL-3 alone in any of the three donors tested. In a total of four experiments performed, HLA-DQ expression by eosinophils treated with IL-3 in the absence or presence of dexamethasone was as follows: donor 1, 6.3 > 8.0; donor 2, 9.9 > 50.5; donor 3, 3.6 > 5.2, and 3.4 > 2.8 percent positive cells. Thus, although IL-3 appears the more potent cytokine for MHC induction, dexamethsone appears to act in a similar fashion to enhance both IL-3 and GM-CSF-induced MHC class I1 expression by eosinophils.
Effect of dexamethasone on IL-%induced expression of HLA class II on eosinophils. A previous study5 has shown weak induction of HLA-DR on human eosinophils cultured for 48 hours with L-5, and therefore, the effect of dexamethasone with this cytokine was tested. Eosinophils cultured in the presence of 0.5 to 50 ng/mL IL-5 showed modest induction of HLA-DR antigens (Fig 4A) . The mean level of HLA-DR induced by IL-5 (32% ? 21%, n = 10) was considerably lower than that observed after stimulation with GM-CSF or IL-3 (53% 2 23%, n = 13; and 92% t 8%, n = 4, respectively). However, in all cases, dexamethasone greatly enhanced IL-5-induced expression of HLA-DR with optimal enhancement occurring with lo-* m o m or greater concentrations of dexamethasone. Enhancement of IL-S-induced HLA-DR expression was seen in 10 experiments (seven donors) the mean ? SD induction with IL-5 alone being 32% 2 21%, and with IL-5 plus dexamethasone, 64% I 20%.
Although IL-5 alone did not induce HLA-DP expression by eosinophils, dexamethasone plus IL-5 induced expression in six of seven donors (Fig 4B shows HLA-DP expression for a representative donor). IL-5 failed to induce HLA-DQ expression by any of the donors tested in the presence or absence of dexamethasone. Thus, a hierarchy appears to exist between the three cytokines for inducibility of MHC class I1 expression by eosinophils, with IL-3 the most potent and IL-5 the least. Although data are presented as percent positive eosinophils, this hierarchy is also apparent when data are expressed as log mean fluoresence intensity of class I1 expression. Thus, in a representative experiment, log mean fluorescence intensity for HLA-DR after optimal stimulation with IL-3, GM-CSF, and IL-5 were 99, 24, and 13, respectively, where staining with control antibody was less than 7 for all treatments.
When the kinetics of HLA-DR expression on eosinophils cultured with IL-5 was investigated, expression was barely detectable on the second day of culture (8% positive cells; GM-CSF-treated cells, 38%), although this was doubled by the presence of 10" mol/L dexamethasone (Fig 5A) . IL-5-induced expression was maximal by day 4 of culture (21% positive cells) and this level was maintained at day 6. Dexamethasone increased the expression of HLA-DR at day 4 (53% positive cells) and this enhancement was maintained on day 6 of culture. The weaker induction of MHC class I1 expression by IL-5 may account for the much greater increase observed in the presence of dexamethasone as compared with GM-CSF and IL-3.
On the basis of the above results, we postulated that the effects of IL-5 may be indirect, perhaps by inducing the synthesis of other cytokines such as GM-CSF or IL-3 by eosinophils. To test this hypothesis and to prove that induction by GM-CSF and IL-3 was specific, neutralizing antibod- ies to these two cytokines were tested for their capacity to inhibit MHC class I1 expression. In the experiment shown in Table 1 , IL-5 alone induced 7% of eosinophils to express HLA-DR, and XL-5 plus dexamethasone, 32%. Antibodies to IL-3 or GM-CSF, either alone or in combination, failed
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expression when tested between 10" and 10"omoliL. In a separate experiment, a third nonglucocorticoid steroid, vitamin D3, was also found to have no effect on IL-5-induced expression of HLA-DR or DP (data not shown).
Effect of dexamethasone on cytokine-induced expression of ICAM-l. Previous studies have shown that sputum eosinophils from symptomatic asthmatics express HLA-DR and the adhesion molecule ICAM-1,6 and that cultured peripheral blood-derived eosinophils can be induced to express ICAM-I by cytokine stim~lation.~ These antigens are believed important in the documented capacity of eosinophils to present antigen to T lymphocytes in
The effect of dexamethasone on cytokine-induced expression of ICAM-1 was investigated in parallel with HLA-DR. Culture of eosinophils for 6 days with 50 U/mL GM-CSF induced 69% of the viable cells to express ICAM-1 in one donor (8% positive on day 0). Dexamethasone markedly inhibited GM-CSF-induced ICAM-1 expression in this experiment (23% positive cells), in contrast with the enhancement of MHC class I1 expression observed (HLA-DR, 12% and 40% positive cells; HLA-DP, 8% and 33% in the absence and presence of dexamethasone, respectively; Fig 2A) . Dexamethasone inhibited GM-CSF induction of ICAM-1 expression: in 11 experiments, mean ICAM-1 expression by eosinophils cultured with cytokine, without or with m o a dexamethasone was 35% ? 23% and 15% ? 7%, respectively. Expression of ICAM-1 was also induced by both IL-3 and IL-5, and dexamethasone inhibited expression in a dosedependent manner at each concentration of IL-5 tested ( Fig  4C) and in two of three experiments where induction by IL-3 was studied (data not shown), Thus, dexamethasone shows contrasting effects on ICAM-1 and class I1 expression, two important components of a cell's capacity to present antigen to T cells.
Expression by eosinophils of a second costimulatory molecule, B7/BB1 (CDSO), which has a clearly documented role in T-cell activation was also studied? No constitutive to inhibit the level of expression induced with both IL-5 and dexamethasone (Table 1 ). In the same experiment, the effects of IL-3 and GM-CSF were inhibited by the appropriate antibody. Therefore, these experiments show that MHC class I1 induction by IL-5 in the presence of dexamethasone is not mediated by IL-3 or GM-CSF.
A comparison of the capacity of other steroid hormones to upregulate MHC class II expression. The specificity of the dexamethasone mediated enhancement of MHC class 11 expression was investigated by using a second glucocorticoid, hydrocortisone, and three nonglucocorticoid steroids. Dexamethasone and hydrocortisone both produced a dosedependent enhancement of IL-5-induced expression of HLA-DR (Fig 5B) . Similar results were obtained with GM-CSFstimulated eosinophils (data not shown). However, in line with the known pharmacologic potency of these glucocorticoids, hydrocortisone appears to be 10-to 100-fold less active than dexamethasone. Two nonglucocorticoid steroids tested, ,&oestradiol and DHEA, had no effect on class I1 expression of B7 on purified eosinophils was observed, despite strong immunostaining of Epstein-Barr virus-transformed B cells with the same reagent (data not shown). GM-CSF, in the presence or absence of dexamethasone, failed to induce B7 expression on eosinophils isolated from two separate donors (data not shown). Furthermore stimulation of eosinophils with GM-CSF or GM-CSF plus IFNy in the presence or absence of dexamethasone failed to induce B7 expression.
The effect of dexumethusone treutment on the antigen presenting function of eosinophils. Dexamethasone partially inhibits ICAM-l expression while enhancing MHC class I1 expression. To assess the potential functional relevance of exposure of eosinophils to cytokine and dexamethasone, the capacity of the different eosinophil populations to present antigen to the T cell clone HA1.7 (DR1 restricted; specific for the hemagglutinin peptide 307-319) was examined. Eosinophils from a DRl and a DR8 donor were stimulated for 24 hours with 50 U/mL GM-CSF in the presence or absence of IO-' m o m dexamethasone. Cytokine stimulated eosinophils from the DR1 donor presented peptide to the Tcell clone, and the amount of proliferation was proportional to the number of eosinophils present (Fig 6) . Dexamethasone-treated eosinophils showed enhanced presentation of the peptide compared with cells stimulated by cytokine alone. Presentation appeared to be DR restricted because eosinophils purified from a donor of the inappropriate DR8 haplotype failed to present peptide. Although measurements were made after only 1 day of culture, GM-CSF induced HLA-DR expression was enhanced by dexamethasone in both donors, whereas ICAM-l expression was partially inhibited. Thus, dexamethasone and GM-CSF increase the antigen-presenting activity of eosinophils corresponding to the increase in class I1 expression, despite the decrease in ICAM-
1.
DISCUSSION
We have examined the effect of glucocorticoid hormones on cytokine-induced MHC class I1 antigen expression by human eosinophils. Three major conclusions can be drawn from our study. Firstly, glucocorticoids upregulate IL-3, IL-S , and GM-CSF induction of HLA-DR and -DP expression by eosinophils. Secondly, this effect appears to be glucocorticoid specific because dexamethasone and hydrocortisone, but not three nonglucocorticoid steroid hormones, mediate this effect. Finally, treatment with dexamethasone and cytokines augments the antigen-presenting cell function of eosinophils to cloned T lymphocytes.
IL-5 was observed to be a much weaker inducer of MHC class I1 antigen expression by eosinophils than IL-3 and GM-CSF, inducing low levels of HLA-DR, but no HLA-DP expression. Nevertheless, dexamethasone had a much greater effect on IL-5 than on IL-3-or GM-CSF-induced antigen expression, and it seems likely that this reflects the much weaker induction by cytokine alone. In this respect, it is noteworthy that similar to the effect of IL-S on eosinophils. synergy is observed between GM-CSF or 1L-3 and dexamethasone for upregulation of HLA-DR, HLA-DP, and HLA-DQ antigen expression on purified monocytes. On monocytes, these cytokines alone either fail to upregulate or induce very low levels of antigen expression." In contrast with the enhancement by dexamethasone of hematopoietic growth factor-induced MHC class I1 expression, induction by IFNy was inhibited by glucocorticoids under the same experimental conditions. IL-3, IL-5, and GM-CSF, but not IFNy, belong to a family of cytokines that share many functional similarities. These cytokines share a common P chain of their heterodimeric cytokine receptor molecule that combines with unique (Y chains (IL-3a, IL-Sa, and GM-CSFa) to confer specificity for each cytokine. These shared receptor properties are likely to represent a common signal transduction pathway distinct from that induced by IFNy, and therefore, reflect a common mechanism of glucocorticoid action for enhancement of MHC antigen e x p r e s~i o n . class I1 antigens observed throughout this study and in at least one independent report: This was apparent both when HLA-DR expression was expressed as percent positive cells, and more strikingly, when data were presented as mean fluorescence intensity values. In addition, IL-3, in the presence or absence of dexamethasone, was able to induce the greatest levels of HLA-DP in all individuals. Similarly, although none of the three hematopoietic growth factors alone induced expression of HLA-DQ, induction was observed in one donor when eosinophils were stimulated with IL-3 plus dexamethasone. These experiments show not only the greater capacity of IL-3 to induce MHC class I1 antigens, but also imply differential regulation of HLA-DQ as compared with HLA-DR and perhaps HLA-DP on eosinophils. The reason why it is more difficult to upregulate HLA-DQ expression and whether some individuals are completely unable to upregulate HLA-DQ remain important issues to address.
The enhancement of MHC class I1 expression was found to be glucocorticoid specific. Three nonglucocorticoid steroids, @-oestradiol, DHEA, and vitamin D3 had no effect on induction of MHC class I1 antigen expression by eosinophils. A second glucocorticoid, hydrocortisone, also enhanced HLA-D antigen expression induced by hematopoietic growth factors. However, hydrocortisone was considerably less potent than dexamethasone, requiring a 10-to 100-fold higher concentration than dexamethasone to achieve similar enhancement of MHC class I1 expression. These results are consistent with the known pharmacologic potency of these mediators."
In contrast with the potent augmentative effects of glucocorticoids and cytokines on HLA-D antigens, expression of ICAM-1 was reduced. In addition, we were unable to detect expression of B71BBl by eosinophils with any of the treatments tested. Because all these functions are believed important for T-cell activation, the effect of glucocorticoid treatment on the antigen-presenting function of eosinophils was assessed. Glucocorticoid-treated eosinophils induced greater proliferation of an influenza peptide-specific T-cell clone than those treated with cytokine alone. Although glucocorticoids greatly enhance MHC antigen expression by eosinophils, the levels observed are still significantly lower than those on "professional" antigen-presenting cells such as macrophages, dendritic cells, or B lymphocytes. Considerable functional heterogeneity exists among different antigenpresenting cell populations that is likely to greatly influence the T-cell response that develops after antigenic challenge. Although dendritic cells may be better able to initiate primary immune responses, we envisage that other "nonprofessional" antigen-presenting cells, such as eosinophils, may be better able to present antigen to already-activated T cells, which require less costimulatory function, and thus, maintain ongoing immune responses.
The physiologic significance of the enhanced MHC class I1 expression and enhanced antigen-presenting cell function by glucocorticoids in vitro is intriguing. Glucocorticoids at the concentrations found to be effective in this study are within the levels thought to be active physiologically and achieved pharmacologically, At sites of allergic inflammation, mRNA specific for cytokines such as GM-CSF, IL-3, IL-4, and IL-532,33 has been detected and is thought to derive variously from T cells, macrophages, and eosinophils. However, T cells synthesising m y , the other principal mediator inducing MHC class I1 expression, are absent. Because eosinophils recovered from inflammatory sites, such as the sputum of asthmatics, show significant expression of HLA-DR,6,7 a role for hematopoeitic growth factors with either endogenous or exogenously derived glucocorticoids in regulating these molecules in vivo is possible.
The observation of synergy between glucocorticoids and hematopoeitic growth factors in the induction of MHC class I1 antigens and enhancement of antigen presentation is in contrast with the perceived role of glucocorticoids as antiinflammatory and immunosuppressive mediators. These steroids are used as immunosuppressive agents for the treatment of conditions as diverse as leukemia, prevention of transplant rejection, systemic lupus erythematosus, and vasculitides. Their mode of action is thought, at least in part, to be caused by their potent inhibition of cytokine production including IL-1, IL-2, IL-3, IL-6, IL-8, GM-CSF, and TNF, but not MHowever, there is now a growing body of evidence, in addition to the present study, that glucocorticoids also have certain noninhibitory properties. These include the capacity to upregulate IL-6 receptor expression on epithelial cells, and IL-1 receptor expression on peripheral blood and bone marrow cells.3'*40 These data lead to the generation of a complex picture: treatment with glucocorticoids leading variously to downregulation of cytokine availability, including hematopoeitic growth factors and decreased recruitment of eosinophils to the inflammatory site. In contrast, glucocorticoids also mediate upregulation of cytokine receptor and enhancement of MHC class I1 expression. Studies on the effect of glucocorticoid therapy on MHC class I1 expression on sputum eosinophils from asthmatics may provide a clearer picture of the dominant effects of glucocorticoids in vivo. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
